Medical Oncology

Rheumatology   

Questions discussed in this category

In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?
Acknowledging that there is no time for good trials yet in this setting
1 Answer available
Is your approach to managing immune related adverse events altered at all in light of COVID-19?
2 Answers available
How do you approach further treatment of patients who develop grade 2-3 immune colitis from nivolumab/ipilimumab prior to completion of the 4 ipilimumab doses?
Do you re-challenge with nivolumab alone, change from nivo 1/ipi 3 to nivo 3/ipi 1 upon re-challenge, or stop immunotherapy altogether if grade 3?&nbs...
1 Answer available
Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?
1 Answer available
Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?
1 Answer available
Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?
1 Answer available
How do you identify immunotherapy-related pneumonitis vs. radiation pneumonitis in a patient status post chemoradiation receiving consolidation immunotherapy?
Is IO related pneumonitis in the radiation field or more diffuse?
1 Answer available
How do you counsel an early stage breast cancer patient with lupus regarding decisions on radiation?
3 Answers available
In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it consider safe to give immune checkpoint blockers?
1 Answer available
Do you use immune checkpoint inhibitors in NSCLC patients with pre-existing, well-controlled autoimmune disease?
Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?
1 Answer available


Papers discussed in this category

Annals of internal medicine, 2018-01-16
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
Radiographics : a review publication of the Radiological Society of North America, Inc, 2004
Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
J Immunother Cancer, 2019 Aug 22
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.
Journal for immunotherapy of cancer, 2017-11-21
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Cancer management and research, 2017
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.
Lancet Oncol., 2020 Mar 03
Risk of COVID-19 for patients with cancer.
Lancet, 2020 Feb 07
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

Related Topics in Medical Oncology

Copyright © 2020 theMednet
All Rights Reserved.